Clinical trials: Visceral Cancer
Visceral Fat
The Healthy Diet and Lifestyle Study
This pilot study aims to develop a study design to test the difference between a fasting diet and a heart healthy diet, assess participants' adherence to the study design, and to test whether either diet helps to reduce fat…
- Trial name
- HDL (NCT03639350)
- Testing
- IER+MED group, DASH group
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
Breast Cancer
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC
The aim of this trial is to assess if patients treated with the combination of ribociclib and endocrine therapy respond to treatment as fast as patients treated with chemotherapy only, without decreasing their quality of life…
- Trial name
- NCT03905343
- Testing
- Ribociclib, Mono-chemotherapy, Endocrine-Therapy
- Where
- 35 sites in Austria, Belgium and 1 more
- Volunteers
- 25 people
- Sponsor
- Swiss Cancer Institute
Polycystic Ovary Syndrome
The Changes of Body Fat Distribution in Obese Patients With PCOS After LSG
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often…
- Trial name
- NCT04690634
- Testing
- laparoscopic sleeve gastrectomy (LSG)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Shanghai 10th People's Hospital
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
HER2-positive Breast Cancer
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
The purpose of this study is to evaluate the effectiveness of anti-HER2 therapy plus Fulvestrant or Capecitabine in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+)…
- Trial name
- FAVOR (NCT04337658)
- Testing
- Pertuzumab, Trastuzumab, Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 493 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pancreatic Cancer, Visceral Pain
Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study
This is a randomized, double blind controlled, parallel arms trial, aimed to assess the efficacy of pregabalin on pancreatic cancer induced abdominal pain.
- Trial name
- PANPAIN/1 (NCT01768988)
- Testing
- Pregabalin
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Parc de Salut Mar
Sarcoma
Pazopanib Maintenance Phase II
This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant…
- Trial name
- NCT02207309
- Testing
- Pazopanib
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Ovarian Cancer, Low Anterior Resection Syndrome
Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer
This study aims to evaluate the incidence of low anterior resection syndrome and quality of life after cytoreductive surgery for advanced ovarian cancer patients.
- Conditions
- Ovarian Cancer, Low Anterior Resection Syndrome, Quality of Life
- Trial name
- LAPSODY (NCT05431530)
- Testing
- Cytoreductive surgery
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Seoul National University Hospital
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
The goal of this clinical trial is to learn if Trastuzumab Rezetecan (SHR-A1811) is safe and tolerable for patients with HER2-Low unresectable/metastatic breast cancer complicated with visceral crisis.
- Trial name
- NCT07203729
- Testing
- Trastuzumab Rezetecan, Chemotherapy of Physician's Choice
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ovarian Cancer
Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer
Background: Epithelial Ovarian Cancer is the most lethal amongst the gynecologic malignancies and is the fifth leading cause of cancer death in women in the United States.1 Despite initial high response rates, 50% to 75% of women…
- Trial name
- NCT02545010
- Testing
- Paclitaxel, LDWART (Low Dose Whole Abdominal Radiation Therapy)
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer Stage IV
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
This is a multicenter, open-label, randomized controlled, prospective clinical study to evaluate the efficacy and safety of Huaier Granules in patients with advanced breast cancer without visceral metastasis.
- Trial name
- NCT05860907
- Testing
- Huaier Granule
- Where
- 13 sites in China
- Volunteers
- 384 people
- Sponsor
- Fudan University
Advanced Breast Cancer
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
This is a multicenter, single-arm, open-label, Simon's two-stage exploratory clinical trial. 18 eligible patients with advanced breast cancer with visceral crisis will enroll in stage I.
- Trial name
- NCT05431504
- Testing
- Dalpiciclib in combination with endocrine therapy by Physicians choice
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer, Sarcopenia
Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients
This study aims to create a clinical prediction model. Abdominal fat and muscle area also play an important role in the prediction of surgical outcomes in colorectal cancer.
- Conditions
- Colorectal Cancer, Sarcopenia, Obesity and Overweight
- Trial name
- NCT06614699
- Testing
- abdominal fat and muscle area
- Where
- 3 sites in China
- Volunteers
- 8,000 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Triple-Negative Breast Cancer
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
This is a prospective, multicenter, open-label, randomized, and controlled trial to test the superiority of EndoTAG®-1 in combination with paclitaxel and gemcitabine versus paclitaxel in combination with gemcitabine.
- Trial name
- NCT03002103
- Testing
- EndoTAG-1, Paclitaxel, Gemcitabine Hydrochloride
- Where
- 6 sites in Taiwan
- Volunteers
- 420 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Pain, Cancer
Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
This study evaluates colonic analgesia by comparing two novel formulations, GIC-1001 and GIC-1002 with placebo using a barostat distender.
- Conditions
- Pain, Cancer, Colonic Disease
- Trial name
- NCT02276768
- Testing
- GIC-1001 375 mg TID, GIC-1001 500 mg TID, GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- gicare Pharma Inc.
Metabolic Syndrome, Gastric Cancer
Omentectomy for Metabolic Syndrome in Gastric Cancer Patients
Many features of the metabolic syndrome are associated with insulin resistance. And, metabolic syndrome and insulin resistance are related to visceral obesity.
- Trial name
- NCT02641925
- Testing
- Omentum preserving, Total omentectomy
- Where
- 3 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Keimyung University Dongsan Medical Center
Colonic Neoplasms
Laparoscopic Versus Open Surgery for Colon Cancer With Visceral Obesity
This study aims to elucidate whether there is a difference in long-term prognosis between laparoscopic surgery and open surgery in colon cancer patients with visceral obesity.
- Trial name
- LOVO (NCT07314996)
- Testing
- Laparoscopic surgery, Open surgery
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to…
- Trial name
- NCT05645523
- Testing
- Indocyanine Green
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Metabolic Syndrome as Breast Cancer Risk Factor
Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer
Healthy women and women with breast cancer have been enrolled in our nested case-control study between 2008 and 2009 in order to evaluate the association between metabolic syndrome and breast cancer, analyzing anthropometric…
- Trial name
- NCT01172886
- Where
- Italy
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- Sbarro Health Research Organization
Breast Cancer
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
This study is an open-label, multicenter, randomized controlled study. It is planned to include 258 patients with HR +/HER2- advanced breast cancer with visceral metastases.
- Trial name
- NCT07467330
- Testing
- dalpiciclib + capecitabine + endocrine therapy, dalpiciclib + endocrine therapy
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Fujian Cancer Hospital